TRDV2: A Potential Drug Target and Biomarker (G28517)

Target Name: TRDV2

NCBI ID: G28517

TRDV2

Other Name(s): T cell receptor delta variable 2 | hDV102S1

TRDV2: A Potential Drug Target and Biomarker

TRDV2, or T cell receptor delta variable 2, is a protein that is expressed in T cells, a type of immune cell that plays a crucial role in protecting the body against infection and disease. TRDV2 is a single transmembrane protein that is composed of two extracellular domains and an intracellular domain. It is characterized by a unique structure that consists of a nucleotide-binding oligomerization (NBO) domain, a carcass domain, and a transmembrane domain.

The NBO domain is a unique feature that is found only in TRDV2. It is composed of a nucleotide-binding oligomerization domain and a scaffold domain that is responsible for the formation of a dimeric complex with nucleotides. This domain is responsible for TRDV2's ability to interact with nucleotides and for the regulation of its function.

The carcass domain is a conserved region that is found in many T cell receptor (TCR) proteins. It is responsible for the formation of the extracellular domain of TRDV2 and is involved in the regulation of its stability and function.

The transmembrane domain is the most well-known part of TRDV2. It is responsible for the formation of the channel that allows TRDV2 to interact with the cytoskeleton and for the regulation of its function.

TRDV2 is a critical protein that is involved in the regulation of T cell receptor (TCR) function. It is a negative regulator of the TCR, which means that it prevents the TCR from being activated by signals from the cell. This is important for the regulation of the immune response and for the control of inflammation.

TRDV2 is also a potential drug target and biomarker. Its unique structure and its involvement in the regulation of TCR function make it an attractive target for manipulation for the treatment of a variety of diseases.

One of the main ways that TRDV2 can be targeted for drug development is through its ability to interact with nucleotides. This interaction makes it possible to develop small molecules that can inhibit or activate TRDV2's function. One of the most promising strategies for the development of TRDV2 inhibitors is the use of small molecules that can bind to the NBO domain of TRDV2.

Another way that TRDV2 can be targeted for drug development is through its role in the regulation of TCR function.TRDV2 is a negative regulator of the TCR, which means that it prevents the TCR from being activated by signals from the cell. This can be leveraged to develop drugs that can inhibit TCR function and the regulation of T cell responses.

In addition to its potential as a drug target, TRDV2 is also a potential biomarker for a variety of diseases. Its unique structure and its involvement in the regulation of TCR function make it an attractive target for the development of diagnostic tools.

TRDV2 is a protein that is involved in the regulation of T cell receptor (TCR) function. Its unique structure and its ability to interact with nucleotides make it an attractive target for the development of drugs and biomarkers.

Protein Name: T Cell Receptor Delta Variable 2

Functions: V region of the variable domain of T cell receptor (TR) delta chain that participates in the antigen recognition (PubMed:24600447). Gamma-delta TRs recognize a variety of self and foreign non-peptide antigens frequently expressed at the epithelial boundaries between the host and external environment, including endogenous lipids presented by MH-like protein CD1D and phosphoantigens presented by butyrophilin-like molecule BTN3A1. Upon antigen recognition induces rapid, innate-like immune responses involved in pathogen clearance and tissue repair (PubMed:28920588, PubMed:23348415). Binding of gamma-delta TR complex to antigen triggers phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains by the LCK and FYN kinases, allowing the recruitment, phosphorylation, and activation of ZAP70 that facilitates phosphorylation of the scaffolding proteins LCP2 and LAT. This lead to the formation of a supramolecular signalosome that recruits the phospholipase PLCG1, resulting in calcium mobilization and ERK activation, ultimately leading to T cell expansion and differentiation into effector cells (PubMed:25674089). Gamma-delta TRs are produced through somatic rearrangement of a limited repertoire of variable (V), diversity (D), and joining (J) genes. The potential diversity of gamma-delta TRs is conferred by the unique ability to rearrange (D) genes in tandem and to utilize all three reading frames. The combinatorial diversity is considerably increased by the sequence exonuclease trimming and random nucleotide (N) region additions which occur during the V-(D)-J rearrangements (PubMed:24387714)

The "TRDV2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRDV2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets